Winningham Rick E 4
4 · Theravance Biopharma, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Winningham Rick E
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Award
Ordinary Shares
2025-02-28$9.35/sh+2,178$20,364→ 1,778,144 total
Holdings
- 3,900(indirect: As Custodian)
Ordinary Shares
- 92,567(indirect: By Trust)
Ordinary Shares
Footnotes (1)
- [F1]Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on February 28, 2025.